CMO Selection: Risk vs. Cost Trade-offs
Evaluate CMO partnerships by analyzing cost, supply chain resilience, regulatory timelines, and capital constraints under uncertainty
Phase 2 complete. FDA conditional approval in 18 months. Series B funding: 60% of target. Secure manufacturing capacity now. Which CMO pathway do you recommend? Decision required within 2 weeks Singapore CMO (30% cost savings) Proven Pennsylvania CMO (40% premium, dual-sourced) Hybrid: In-house + Small CMO Partner Build-as-you-go Timeline Robustness Ability to meet FDA conditional approval in 18 months Cost Efficiency Runway preservation post-Series B Supply Chain Resilience Risk mitigation from single/dual sourcing Capital Availability Feasibility given constrained funding Learner adjusts weights based on risk tolerance; scoring recalculates Which two risks concern you most? Rank: (a) Supply chain disruption, (b)…
Sign up free — one personalized lesson every day, matched to your role and goals.
Already have an account? Sign in